NUDT16L1

Across TCGA pan-cancer cohorts, NUDT16L1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NUDT16L1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NUDT16L1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NUDT16L1 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

HNSC, CCRCC, and LUAD are the cancer types where NUDT16L1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NUDT16L1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.178	<.001	8	view →
CCRCC	All	All	−0.125	<.001	6	view →
LUAD	All	All	+0.150	<.001	5	view →
COAD	All	All	−0.087	.005	4	view →
LSCC	All	All	−0.094	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NUDT16L1–HNSC

Open the HNSC breakdown →